Retrospective Cohort Study
Copyright ©The Author(s) 2016.
World J Transplant. Dec 24, 2016; 6(4): 689-696
Published online Dec 24, 2016. doi: 10.5500/wjt.v6.i4.689
Table 2 Clinical outcomes and follow-up
DSA-A-Bn = 23DSA-Cwn = 12P
Delayed graft function, n (%)7 (30)1 (8)0.216
Acute rejection at 1-yr, n (%)6 (26)3 (25)1
AMR at 1-yr, n (%)6 (26)2 (17)0.685
ACR-only at 1-yr, n (%)01 (8)0.343
1 yr-eGFR (mL/min), median (IQR)51 (46-60)59 (47-64)0.192
1 yr-ProtU, median (IQR)0 (0-0.1)0.1 (0-0.2)0.163
Censored graft failure, n (%)2 (9)00.536
Follow-up time (mo), median (IQR) [range]60 (45-60)18 (11-50)0.001
[28-60][3-60]

  • Citation: Santos S, Malheiro J, Tafulo S, Dias L, Carmo R, Sampaio S, Costa M, Campos A, Pedroso S, Almeida M, Martins LS, Henriques C, Cabrita A. Impact of preformed donor-specific antibodies against HLA class I on kidney graft outcomes: Comparative analysis of exclusively anti-Cw vs anti-A and/or -B antibodies. World J Transplant 2016; 6(4): 689-696
  • URL: https://www.wjgnet.com/2220-3230/full/v6/i4/689.htm
  • DOI: https://dx.doi.org/10.5500/wjt.v6.i4.689